Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

被引：0
|
作者：
De La Fuente Burguera, Adolfo [1 ]
Cerchione, Claudio [2 ]
Scholl, Sebastian [3 ]
Middeke, Jan Moritz [4 ,5 ]
Choudhary, Gaurav S. [6 ]
von Roemeling, Reinhard [6 ]
Platzbecker, Uwe [7 ]
机构：
[1] MD Anderson Canc Ctr, Madrid, Spain
[2] IRCCS, Ist Sci Romagnolo Studio Cura Tumori IRST, Meldola, FC, Italy
[3] Jena Univ Hosp, Klin Innere Med 3, Jena, Germany
[4] Tech Univ Dresden, Else Kroner Fresenius Ctr Digital Hlth, Dresden, Germany
[5] Tech Univ Dresden, Dresden, Germany
[6] Curis Inc, Lexington, MA USA
[7] Univ Hosp Leipzig, Dept Hematol, Leipzig, Germany
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190125
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
    Sekeres, Mikkael A.
    Schuster, Michael W.
    Joris, Magalie
    Krauter, Jurgen
    Maertens, Johan A.
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ma, Weidong Wendy
    Zeremski, Mirjana
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    BLOOD, 2019, 134
  • [42] Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
    Handa, Hiroshi
    Cheong, June-Won
    Onishi, Yasushi
    Iida, Hiroatsu
    Kobayashi, Yukio
    Kim, Hyeoung-Joon
    Chiou, Tzeon-Jye
    Izutsu, Koji
    Tsukurov, Olga
    Zhou, Xiaofei
    Faessel, Helene
    Yuan, Ying
    Sedarati, Farhad
    Faller, Douglas V.
    Kimura, Akiko
    Wu, Shang-Ju
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [43] A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML)
    Daver, Naval Guastad
    Montesinos, Pau
    Aribi, Ahmed M.
    Martinelli, Giovanni
    Wang, Eunice S.
    Altman, Jessica K.
    Roboz, Gail J.
    Burke, Patrick William
    Walter, Roland B.
    Begna, Kebede
    Sloss, Callum Mortimer
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Sweet, Kendra Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial
    Peterlin, Pierre
    Garnier, Alice
    Le Bourgeois, Amandine
    Guillaume, Thierry
    Le Bris, Yannick
    Theisen, Olivier
    Bene, Marie C.
    Eveillard, Marion
    Rimbert, Marie
    Jullien, Maxime
    Planche, Lucie
    Gaschet, Joelle
    Chevallier, Patrice
    ECLINICALMEDICINE, 2023, 64
  • [45] KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/ Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia
    Zeidan, Amer
    Fathi, Amir
    Issa, Ghayas
    Erba, Harry
    Ahsan, Julie Mackey
    Corum, Daniel
    Tomkinson, Blake
    Kozlek, Tom
    Leoni, Mollie
    Wang, Eunice
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S308 - S309
  • [46] Blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia: An open-label, single-arm, multicenter confirmatory phase 2 study
    Topp, M. S.
    Goekbuget, N.
    Stein, A. S.
    Bargou, R. C.
    Dombret, H.
    Fielding, A. K.
    Ribera, J. M.
    Foa, R.
    Zugmaier, G.
    Jia, C.
    Maniar, T.
    Huber, B.
    Nagorsen, D.
    Kantarjian, H. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 181 - 181
  • [47] A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.
    Daver, Naval Guastad
    Montesinos, Pau
    Altman, Jessica K.
    Advani, Anjali S.
    Wang, Eunice S.
    Garciaz, Sylvain
    Martinelli, Giovanni
    Roboz, Gail J.
    Walter, Roland B.
    Begna, Kebede
    Lunghi, Monia
    Platzbecker, Uwe
    Vyas, Paresh
    Burke, Patrick William
    Curti, Antonio
    DeAngelo, Daniel J.
    Gastaud, Lauris
    Schliemann, Christoph
    Oshrine, Benjamin
    Sallman, David Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
    DiNardo, Courtney D.
    Schuh, Andre C.
    Stein, Eytan M.
    Montesinos, Pau
    Wei, Andrew H.
    de Botton, Stephane
    Zeidan, Amer M.
    Fathi, Amir T.
    Kantarjian, Hagop M.
    Bennett, John M.
    Frattini, Mark G.
    Martin-Regueira, Patricia
    Lersch, Frederik
    Gong, Jing
    Hasan, Maroof
    Vyas, Paresh
    Doehner, Hartmut
    LANCET ONCOLOGY, 2021, 22 (11): : 1597 - 1608
  • [49] A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval
    Vyas, Paresh
    Chao, Mark
    Xing, Guan
    Renard, Camille
    Ramsingh, Giri
    Sallman, David A.
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [50] A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval
    Vyas, Paresh
    Chao, Mark P.
    Xing, Guan
    Renard, Camille
    Ramsingh, Giri
    Sallman, David A.
    Wei, Andrew H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S5 - S6
12345